Neurocrine Biosciences, Inc. (NASDAQ:NBIX) currently has a daily average trading volume of 857.94K but it saw 1758814 shares traded in last market. With a market cap of 12.97B USD, the company’s current market price of $128.43 came rising about 3.77 while comparing to the previous closing price of $123.76. In past 52 weeks, the stock remained buoying in the range of price level as high as $157.98 and as low as $103.63. In the recent trading on the day, stock has struck highest price mark of $125.02 while lowest mark touched by it was $129.5.
Taking a look at 20-day trading activity of Neurocrine Biosciences, Inc. (NBIX) gives us an average price of $146.66, while its current price level is -18.70% below from 52-week high level whereas it is 23.93% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $144.00 while that of 200 days or SMA-200 reads an average of $135.64. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.14% during that period while stretching the period over a month that decreases to 2.91%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 32.89 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Piper Sandler which upgraded the stock as “Overweight” in its note to investors issued on August 29, 2024, recommending a price target of between $131 and $159 for it. Wells Fargo upgraded its recommendation for the stock as a “Overweight” from “Equal Weight” on April 24, 2024 while assigning a price target range of $140-$170. Citigroup issued its recommendations for the stock as it resumed the price target for the stock is $127.
Over the week, NBIX’s stock price is moving -15.82% down while it is -9.28% when we observe its performance for the past one month. Year-to-date it is -2.53% down and over the past year, the stock is showing an upside performance of 20.15%.
Currently, Neurocrine Biosciences, Inc.’s total number of outstanding shares is 100.98M. Company’s return on investment (ROI) stands at 12.27% and return on equity (ROE) at 15.55%. It has a price to earnings ratio (P/E ratio) of 38.80 while having a 18.68 of forward P/E ratio. Stock’s beta reads 0.37. Stock has a price to book (P/B) ratio of 5.16 while price to sale or P/S ratio amounts to 6.12. Its return on asset (ROA) is 11.46% on average.
